Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCgp100 versus investigator's choice in previously untreated advanced uveal melanoma
NL-OMON48897Phase 2Active, not recruiting
- Sponsor
- Immunocore
- Start
- Mar 2019
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tebentafusp in intraocular melanoma and eye melanoma (2 arms), sponsored by Immunocore. Primary endpoint: overall survival. Started Mar 2019; status: active, not recruiting.
02
Drugs
tebentafusp
03
Conditions
intraocular melanomaeye melanoma
Beyond the preview
Go deeper on NL-OMON48897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48897.